ALK and non-small cell lung carcinoma: Alwithenani et al. used camrelizumab in combination with carboplatin + pemetrexed for the first-line treatment of advanced/metastatic EGFR/ALK mutation-negative nonsquamous non-small-cell lung cancer, which significantly prolonged the PFS and reduced the risk of death by 27% [18].